Our parent company, Sorrento Therapeutics, Inc. (NASDAQ: SRNE) has developed G-MAB technology, one of the largest and most diverse fully human antibody libraries in the industry. This antibody library platform was designed to facilitate the rapid identification and selection of highly specific monoclonal antibody (mAb) therapeutic product candidates.

Sorrento’s library achieves its high diversity from a large collection of high-quality antibodies. The theoretical diversity of our library has been calculated to be more than ten quadrillion (10E16) unique antibodies, making it one of the largest fully human antibody library available to pharmaceutical and biotechnology companies for drug discovery and development partnerships. Exemplary of the uniqueness of the library quality are Sorrento’s immunomodulatory anti-PD1 and anti-PD-L1 mAbs, which are, to the company’s knowledge, the only mAbs targeting PD-1 and PD-L1 in development derived from an antibody library. Sorrento has established a comprehensive program aimed at the discovery and development of immunomodulatory antibodies for the treatment of cancer and potentially other disease indications.

Furthermore, the library has also yielded mAbs that target G-protein-coupled receptors (GPCRs), which are important drug targets but have historically been difficult to target using monoclonal antibodies.

Preclinical models demonstrated that Sorrento’s GPCR antibodies have excellent properties resulting in significant reduction in the disease score when evaluated in a mouse model of multiple sclerosis.

Sorrento has advanced over 10 preclinical monoclonal antibody development candidates in the G-MAB pipeline, including those aimed at treatments for oncology and inflammation.